With a HUGE runway of cash I think it´s about time for the investor community to start adding some value to the pipeline. A modest price would be $25M (hey - we are heading for ph IIb w Azixa). That simple calculation would set us for share price of $ 6.50 since we already have $5.50 in pure cash. I have seen some companies trading below cash but those have almost in every case been failing in pivotal trials. MYRX hasn´t. Still valuated to tiny 70% of cash position. Never seen it before.
From a fundamental standpoint the company has already launched what will be a streak of positive news reg the pipeline I think. Azixa will be next in line. It´s time to give the pipeline some value - or at least pay a dollar for a dollar....
I don't understand what you're saying. It sounds like you're trying to form a public pool to make an offer for the company.
The cash on the books is an accounting anomaly. The cost of future clinical trials ought to be there as a debt. As I've pointed out in the "crapshoot" topic, if Azixa turns out to be exactly a nice salvage treatment for GBM (which is all we can be pretty confident of getting right now), the stock price is fair (and Azixa is a commercial mistake).
out of 100 biotechs (micro-/midcaps) - how many of them are trading below cash, huh? There is ALMOST always a (sometime VERY heavy) premium to the cash position. It�s known as technology value. I think we have a pretty exciting pipeline here that should be worth something. I said $25M, it could as well be the double- I�m conservative.
We have substansial upside from here - without ph IIb data.